

Title:
Immune mediated colitis caused by lung cancer treatment with atezolizumab

Authors:
Santiago González Vázquez, Susana de la Riva Onandía, José Ignacio Echeveste, Miguel Muñoz Navas

DOI: 10.17235/reed.2017.5060/2017

Link: [PubMed \(Epub ahead of print\)](#)

Please cite this article as:
González Vázquez Santiago, de la Riva Onandía Susana, Echeveste José Ignacio, Muñoz Navas Miguel. Immune mediated colitis caused by lung cancer treatment with atezolizumab. Rev Esp Enferm Dig 2017. doi: 10.17235/reed.2017.5060/2017.

Enero 2017 • Volumen 109 • Número 1 • Páginas 1-86

Revista Española de Enfermedades Digestivas
THE SPANISH JOURNAL OF GASTROENTEROLOGY

Acceso al texto completo en: www.reed.es o www.sped.es

Factor de impacto 100 (ISI) JCR: 1.455 (2016)
SCR: 0.34 (2016)

ORGANO OFICIAL DE:
SOCIEDAD ESPAÑOLA DE PATOLOGÍA DIGESTIVA, SOCIEDAD ESPAÑOLA DE ENDOSCOPIA DIGESTIVA Y ASOCIACIÓN ESPAÑOLA DE ECOGRAFÍA DIGESTIVA

SEPOD

Editorial Colitis diverticular bleeding. Have we identified the risk factors for massive bleeding yet? J. W. Bercian Valencia	Lesión de Bowdener: diagnóstico por gastroscopia R. Barrio Iglesias, M. N. Barrio Irujo, M. Paz Noya y J. E. Dominguez Muñoz	65
Trabajos Originales Risk factors for severity and recurrence of colitis diverticular bleeding N. Argente, P. Cabrita, A. Arduini, M. Escobar and N. Guzmán	Notas Clínicas Colitis crónica idiopática: a case report and review of the literature focusing in the presentation of subacute-onset M. de Alaveda-Nemón, V. L. Barrio-Cabral and S. L. Lopera	67
Microsporidian and inflammatory bowel disease: the other diagnosis? J. Barrio, A. Argente, V. L. Barrio-Cabral, J. Castro, M. Acari-Barris, M. Hernández-Serra, C. García, M. de la Cruz, D. Barrio and A. López-García	Herangopercutánea patética. Una localización infrecuente de tumor estromal I. Alcala Abad, J. M. García-Cerdillo, L. Aguirre-Duñabe, A. M. Quintana-Rivero y A. Colla-Morero	69
Influence of sustained 48h response on the regression of fibrosis and portal hypertension in cirrhotic HCV patients treated with antiviral therapy A. Barrio, J. Cabrita, M. J. López-Alcalá, I. L. Fariña, M. T. Arán, A. Galván, F. Castiella, E. Fabrega and J. Crespo	Hemólisis por eritropoiesis supresora intracerebral C. Pizarro-Carras, A. Escobedo-Sánchez, M. A. Paredes-Capó, J. Arangul-Arribas y C. García-Delgado	70
Malnutrition risk questionnaire combined with body composition measurement in malnutrition screening in inflammatory bowel disease A. A. Cortés, A. Muñoz, Z. Pili, I. Pall and P. Muñoz	Endoscopia: removal of intubated large varicose gastric: a case report M. Oquendo and C. Soler-Munoz	73
A survey-based analysis on endoscopic quality indicators compliance among Spanish endoscopists I. Fernández-Cruz, F. Argente, P. Alonso, J. Soto and S. Soriano	Mesenterico schwannoma: an unusual cause of abdominal mass A. Tapia-Palacio, M. R. Ramos-Vázquez, J. C. Cordero-Ramos, J. Cordero-Lafont and D. L. Carillo-Pérez	76
Revisión Endoscopic resection of colonic polyps in patients on antiplatelet therapy: an evidence-based guideline for clinicians G. Piana, M. Sostero-Salvi, C. Salinas, F. Day and M. J. Gaitan	Cartas al Editor Neoplasia neuroendocrina intestinal, un tumor poco habitual M. de Barrio Noya, J. Barrio Fernández y M. N. Barrio Rodríguez	79
Indicadores en Patología Digestiva Neutrofilos de la arteria mesentérica superior: una causa infrecuente de obstrucción intestinal J. Sempere Jaquez, P. Alcala Barrio y J. C. García-Pérez	Presentación intestinal de tuberculosis por radioterapia post-guante asociada a consumo de Bismuto: patología infrecuente y poco conocida Y. Pineda-Vargas, D. M. Acosta y L. A. Alvarez	80
Neumatosis cística intestinal A. F. Romero-Muñoz y R. Barrio-Zalaga	Parotid endocrino: evidencia for an achalasia patient with multiple esophageal diverticula Y. Su, H. Zhu and D. Liu	81
Neutrofilos de Widal a prueba anti-tuberculosa C. Ochoa-Sandoval, C. C. Hernández-Segura, J. Pineda-Rodríguez y A. N. González-Fernández	Actinobacillus intestinalis: entidades infecciosas en el diagnóstico diferencial de abdomen agudo C. Sánchez-Jiménez, I. Goveas-Noya y J. A. Acosta-Paredes	81
Neutrofilos de Widal a prueba anti-tuberculosa C. Ochoa-Sandoval, C. C. Hernández-Segura, J. Pineda-Rodríguez y A. N. González-Fernández	Perforación múltiple de divertículos de intestino delgado en paciente con síndrome de Ulceras Duodenales R. Fernández-Cruz, A. Barrio-Cabrita y E. Palencia-López	83
Endoscopia: removal of intubated large in a schistosomiasis patient J. L. Barrio-Hernández, M. E. Torres-Castro and M. Torres-Rodríguez	Altopercia anular como manifestación paraneoplásica de un adenoma actinómico gástrico J. Barrio-Cabrita, F. Fernández-Sánchez y J. de la Fuente-Aguado	83
All that glitters is not gold. A different cause for an "alkaline colitis" A. Pineda, M. Su, Y. Villalón and S. Navas	Revisores 2016	85

ARAN

www.reed.es

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

OR 5060

Immune mediated colitis caused by lung cancer treatment with atezolizumab

Santiago González-Vázquez¹, Susana De-la-Riva-Onandía¹, Jose Ignacio-Echeveste² and Miguel Muñoz-Navas¹

Departments of ¹Gastroenterology and ²Pathology. Clínica Universidad de Navarra. Pamplona, Spain

Correspondence: Santiago González-Vázquez

e-mail: gonzalezvazquez santiago@gmail.com

INTRODUCTION

Atezolizumab is an IgG1 isotype monoclonal antibody against the protein programmed cell death-ligand 1 (PD- L1). PD-L1 may be highly expressed in some tumors and is believed to inhibit immune cells that recognize and attack tumor cells. Inhibition of PD-L1 can remove its inhibitory effect and provoke an anti-tumor response.

In October 2016, the Food and Drugs Administration (FDA) approved atezolizumab for the treatment of patients with metastatic non-small cell lung cancer after disease progression during or following platinum based chemotherapy.

CASE REPORT

We present the case of a 43-year-old male with stage IV lung adenocarcinoma in progression, despite standard chemotherapy. He was participating in a clinical randomized trial with four cycles of chemotherapy as follows: cisplatin, pemetrexed and atezolizumab. He showed a good tolerance.

After the last cycle of chemotherapy, he had bloody diarrhea and fever. Stool cultures were negative. A colonoscopy was performed and a pancolitis with a multiple fibrin-coated ulcer was identified. Numerous glandular crypts with cryptic micro-abscesses and a chronic inflammatory lymphoplasmocytic infiltrate were found on biopsy of the colon. These histological findings are similar to those described in ulcerative colitis.

CONCLUSION

Immune mediated colitis is a possible adverse event that is poorly described. It occurs in 19.7% of all patients receiving atezolizumab and requires the administration of corticosteroids for its resolution.

REFERENCES

1. Abdel-Rahman O, ElHalawani H, Fouad M. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: A meta-analysis. *Immunotherapy* 2015;7(11):1213-27. DOI: 10.2217/imt.15.87
2. De Velasco G, Je Y, Bossé D, et al. Comprehensive meta-analysis of key immune-related adverse events from CTLA-4 and PD-1/PD-L1 inhibitors in cancer patients. *Cancer Immunol Res* 2017. pii: canimm.0237.2016. DOI: 10.1158/2326-6066.CIR-16-0237
3. Nishijima TF, Shachar SS, Nyrop KA, et al. Safety and tolerability of PD-1/PD-L1 inhibitors compared with chemotherapy in patients with advanced cancer: A meta-analysis. *Oncologist* 2017. pii: theoncologist.2016-0419. DOI: 10.1634/theoncologist.2016-0419




Fig. 1. Endoscopic biopsy with histopathological features of ulcerative colitis. Depletion of goblet cells, cryptitis and cryptic abscesses suggestive of ulcerative colitis.




Fig. 2. Edematous and erythematous colonic mucosa with ulcers coated with fibrin and whitish exudates.




Fig. 3. Colonic mucosa with increased friability and bleeding when rubbed by the endoscope.

Accepted Article